Why the study?
Although molecular mechanisms for doxorubicin-induced cardiomyopathy were identified, clinical translation remains elusive, prompting a focus on mitochondria as crucial determinants of cardiotoxicity.
This review emphasizes the central role of mitochondrial dysfunction in the pathophysiology of doxorubicin-induced cardiomyopathy, highlighting potential areas for future therapeutic intervention.
Mitochondrial-targeted approaches remain unproven for doxorubicin cardiotoxicity; leaves open whether modulating dynamics or autophagy improves outcomes.
Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer cause of death in DOX-treated patients. Although many different molecular mechanisms explaining the cardiac derangements induced by DOX were identified in past decades, the translation to clinical practice has remained elusive to date. This review examines the current understanding of DOX-induced cardiomyopathy (DCM) with a focus on mitochondria, which were increasingly proven to be crucial determinants of DOX-induced cytotoxicity. We discuss DCM pathophysiology and epidemiology and DOX-induced detrimental effects on mitochondrial function, dynamics, biogenesis, and autophagy. Lastly, we review the current perspectives to contrast the development of DCM, which is still a relatively diffused, invalidating, and life-threatening condition for cancer survivors.
No takes yet. Share an insight, caveat, or question.
Schirone et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: